Pear Therapeutics raises $50m for digital substance use disorder therapies

Pear Therapeutics said today that it closed a $50 million Series B round to help commercialize its prescription digital substance abuse therapies. Temasek led the round and was joined by 5AM Ventures, Jazz Venture Partners, Novartis (NYSE:NVS) and others.

In September, the company’s reSET therapy became the first prescription digital therapeutic approved by the FDA. One month later, it’s reSET-O therapy, designed as an adjunct to pharmacotherapy for people with opioid use disorder, won expedited access pathway designation from the FDA.

Get the full story at our sister site, Drug Delivery Business News.

The post Pear Therapeutics raises $50m for digital substance use disorder therapies appeared first on MassDevice.

from MassDevice http://ift.tt/2lGyFE5